The regulatory toxicology of medical devices is a rapidly evolving field shaped by technological innovation, regulatory harmonization, and the growing use of advanced materials. Unlike pharmaceuticals, medical devices and combination products present unique safety challenges, as their biological effects depend not only on chemical composition but also on physicochemical properties, design, and long-term interactions with tissues. At the center of this evaluation lie the principles of biocompatibility, which ensure that a device performs its intended function without eliciting harmful local or systemic responses on patients.

Research toxicology studies provide the scientific basis for biocompatibility assessments, beginning with in vitro assays and bench tests. These studies, guided by international standards such as ISO 10993 standard series, form the foundation for regulatory toxicology, translating early data into clinically relevant safety assessments. Establishing biocompatibility requires a comprehensive understanding of how materials behave under physiological conditions, including degradation, leachables, and the potential for chronic exposure effects.

The rise of nano-enabled medical devices adds both opportunities and complexities to this framework. Nanomaterials offer unique functionalities—such as improved drug delivery, antimicrobial coatings, and enhanced tissue integration—but their small size, surface reactivity, and potential for biodistribution raise concerns about unforeseen toxicological outcomes. Specialized testing strategies, advanced in vitro models, and mechanistic toxicology approaches are increasingly employed to evaluate the biocompatibility and long-term safety of these novel technologies.

Regulatory agencies are adapting by refining guidance that integrates classical hazard identification with emerging tools such as computational toxicology, predictive modeling, and high-content screening. These approaches not only improve the precision of safety evaluations but also support the principles of the 3Rs (Replacement, Reduction, Refinement of animal testing). Importantly, the integration of biocompatibility into regulatory toxicology ensures that the transition from bench testing to clinical safety reflects both scientific rigor and patient protection.

Ultimately, regulatory toxicology serves as the critical bridge linking material science, biocompatibility testing, and clinical outcomes. Continued collaboration among researchers, regulators, and industry will be essential to develop science-based, globally harmonized frameworks that keep pace with innovation while safeguarding patient health.

Are you interested in contributing a manuscript to this Research Topic?

Regulatory and Research Toxicology of Medical Devices: from Bench Testing to Clinical Safety